In this review
The selected bill is the useful starting number
The current four-month Any-Dose semaglutide offer displays $908 billed every four months, equivalent to $227 per month. Tirzepatide’s corresponding selection displays $1,344 and $336 per month. Both are labeled prepaid. The one-month cards are $277 and $396; the six-month equivalents are $197 and $296. These are different commitments. [1] [2]
The product pages also separate Low-Dose programs from Any-Dose programs. A catalogue’s smaller starting figure cannot silently replace the price of the selected purchase. Compare the provider-approved preparation, actual payment today and renewal amount together. A dose-category selector is a commercial distinction, not permission for the reader to choose a prescription.
Compare complete bills and renewal dates with the full GLP-1 cost planner.
For a different clinical-support and purchase agreement, compare our Joi + Blokes care-and-purchase review.
Two shipments do not mean two payments
The selected four-month cards describe four vials in two shipments, two months apart, with later shipments reschedulable. Free shipping, supplies and unlimited provider support are advertised, and the pages say payment follows approval. Staged dispatch does not change a prepaid term into a monthly installment agreement. [1] [2]
The general agreement permits asynchronous provider messages and says this is not a substitute for primary care. Establish the actual prescriber, dispenser, current state access and follow-up arrangement. A broad support label does not establish scheduled nutrition appointments or included testing; the prescription and service need their own clear scope. [3]
Separate clinical care from dispensing in our clinic-versus-pharmacy-access comparison.
Cancellation wording needs a written resolution
The product cards say cancellation is available before renewal. General terms add a two-month minimum, liability for the remaining minimum-term payments and a forty-eight-hour advance cutoff. Do not promise yourself a prorated exit from a prepaid purchase. Settle the applicable rule and the renewal date before completing the agreement. [1] [2] [3]
The refund policy permits a request before pharmacy processing, described as typically within one day; compounded orders placed with the pharmacy are not ordinarily returnable. Delivery is separate: three to seven business days of processing precede overnight shipment. The policy also addresses remaining beyond-use time, so later dispatch should fit the actual label and prescribed supply. [4]
For a different refund sequence and purchase term, read our RxION term-total and cancellation review.
The commercial comparison does not transfer a branded approval
Levers labels these products compounded and distinguishes its tirzepatide offer from the branded medicine used in a cited trial. Compounded drugs are not FDA-approved; a matching ingredient name does not establish the selected preparation’s safety, effectiveness or quality evaluation. [1] [2] [5]
FDA’s current policy also describes compounding conditions following resolution of the injection shortages. A low-dose label or added ingredient is not a general exemption. Keep the actual patient need and preparation with the prescriber and dispenser, while comparing documented costs and care services as separate consumer decisions. [6]
Keep trial populations and preparations explicit in the semaglutide-versus-tirzepatide evidence.
Understanding the cost
Selected four-month Any-Dose semaglutide: $908 prepaid ($227/month). Tirzepatide: $1,344 prepaid ($336/month). One-month Any-Dose cards $277/$396; six-month equivalents $197/$296. Separate Low-Dose options differ. Confirm actual invoice, supply and renewal.
Build your cost estimateSources
- Levers: semaglutide Any-Dose prepaid program and shipment schedule
- Levers: tirzepatide Any-Dose prepaid program and support
- Levers: clinical roles, subscription minimum and cancellation cutoff
- Levers: pharmacy refund cutoff, delivery and beyond-use policy
- FDA: compounded medicines and limits of premarket review
- FDA: current conditions for GLP-1 compounding after shortage resolution
This review evaluates public service information. It does not claim patient enrollment, product testing or measurement of clinical outcomes.